Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNB1 | Q14721 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.40 |
| ▸ | PTPRA | P18433 | 3/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5355836 | 0.91 | KCNB1 (0.40) | KCNB1ERAP2ERAP1LNPEPPTPN11 | |
| SCHEMBL5371481 | 0.86 | KCNB1 (0.42) | KCNB1ERAP2ERAP1LNPEPPTPN11 | |
| SCHEMBL6254015 | 0.85 | TSHR (0.41) | KCNB1PTPN11PTPN1PTPRAALDH1A1 | |
| SCHEMBL6254035 | 0.84 | POLB (0.41) | PTPN1PTPRAALDH1A1 | |
| SCHEMBL5360875 | 0.82 | PTPN11 (0.44) | KCNB1ERAP2ERAP1LNPEPPTPN11 | |
| SCHEMBL5367299 | 0.82 | PTPN11 (0.46) | ERAP2ERAP1LNPEPPTPN11PTPN1 | |
| SCHEMBL5361015 | 0.81 | KCNB1 (0.44) | KCNB1ERAP2ERAP1LNPEPPTPN11 | |
| SCHEMBL5354728 | 0.77 | AOC3 (0.49) | AOC3LTB4R2 | |
| SCHEMBL5361041 | 0.76 | FNTA (0.47) | KCNB1ERAP2ERAP1LNPEPPTPN11 | |
| SCHEMBL6254029 | 0.76 | LTB4R2 (0.42) | PTPN11LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307078-B2 | Polycyclic compounds which modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-11 | — | — | US | claimed |
| US-7125869-B2 | Polycyclic compounds which modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-10-24 | — | — | US | claimed |
| US-20060009484-A1 | Novel polycyclic compounds which modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-12 | — | — | US | claimed |
| US-7307078-B2 | Polycyclic compounds which modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-11 | — | — | US | disclosed |
| US-20070093487-A1 | 2-[3'-({[6-(2-Methoxyethoxymethoxy)naphthalene-2-carbonyl]methylamino}methyl)biphenyl-4-ylamino]methyl benzoate; dermatology, cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism, cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-04-26 | — | — | US | disclosed |
| US-7125869-B2 | Polycyclic compounds which modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-10-24 | — | — | US | disclosed |
| US-20060009484-A1 | Novel polycyclic compounds which modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-12 | — | — | US | disclosed |
| EP-1572629-A1 | COMPOUNDS WHICH MODULATE PPARϝ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052840-A1 | COMPOUNDS WHICH MODULATE PPARϜ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093487-A1 | 2-[3'-({[6-(2-Methoxyethoxymethoxy)naphthalene-2-carbonyl]methylamino}methyl)biphenyl-4-ylamino]methyl benzoate; dermatology, cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism, cosmetics | MITF, AHR, PAH | KCNB1 507/4885ERAP2 3377/4885ERAP1 4598/4885 |
| US-20060009484-A1 | Novel polycyclic compounds which modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | KCNB1 2228/4885ERAP2 2594/4885ERAP1 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.